Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 8/20 | 0.48 |
| ▸ | CA2 | P00918 | 8/20 | 0.48 |
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA9 | Q16790 | 6/20 | 0.48 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14562406 | 0.97 | MAOA (0.71) | MAOAMAOBMEN1GAAKMT2A | |
| SCHEMBL25354673 | 0.95 | MAOA (0.74) | MAOAMAOBMEN1GAAKMT2A | |
| SCHEMBL2153073 | 0.89 | MAOA (0.57) | MAOAMAOBMEN1GAAKMT2A | |
| SCHEMBL7624292 | 0.89 | MAOA (0.57) | MAOAMAOBMEN1GAAKMT2A | |
| SCHEMBL31526371 | 0.88 | MEN1 (0.57) | MAOAMAOBMEN1GAAKMT2A | |
| SCHEMBL1557057 | 0.87 | TDP1 (0.67) | MAOAMAOBMEN1GAAKMT2A | |
| SCHEMBL18347560 | 0.85 | TDP1 (0.70) | MAOAMAOBMEN1GAAKMT2A | |
| SCHEMBL1298855 | 0.85 | TDP1 (0.70) | MAOAMAOBMEN1GAAKMT2A | |
| SCHEMBL569251 | 0.85 | TDP1 (0.74) | MAOAMAOBMEN1GAAKMT2A | |
| Bromide SCHEMBL25375155 | 0.85 | MAOA (0.65) | MAOAMAOBMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105377875-B | Peptidomimetic affinity ligands for purifying antibodies or antibody fragments | 斯蒂法诺·梅内加蒂 | 2019-11-26 | — | — | CN | disclosed |
| US-10065988-B2 | Peptoid affinity ligands | STEFANO MENEGATTI (US) | 2018-09-04 | — | — | US | disclosed |
| EP-3004136-B1 | PEPTOID AFFINITY LIGANDS FOR THE PURIFICATION OF ANTIBODIES OR ANTIBODY FRAGMENTS | MENEGATTI STEFANO (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-3004136-A1 | PEPTOID AFFINITY LIGANDS FOR THE PURIFICATION OF ANTIBODIES OR ANTIBODY FRAGMENTS | Menegatti, Stefano (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20160075734-A1 | PEPTOID AFFINITY LIGANDS | LIGATRAP TECHNOLOGIES, LLC | 2016-03-17 | — | — | US | disclosed |
| WO-2014194073-A1 | PEPTOID AFFINITY LIGANDS FOR THE PURIFICATION OF ANTIBODIES OR ANTIBODY FRAGMENTS | MENEGATTI STEFANO (US) | 2014-12-04 | — | — | WO | disclosed |
| EP-0680468-B1 | SUBSTITUTED AMINO COMPOUNDS, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THROMBOCYTE AGGREGATION | HOECHST AG (DE) | 1998-06-24 | — | — | EP | disclosed |
| US-5681838-A | ALSO FOR SUPPRESSING CANCER CELL METASTASES AND BINDING OF OSTEOCLASTS TO BONE SURFACES | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-10-28 | — | — | US | disclosed |
| US-5668290-A | CEPHALOSPORIN DERIVATIVES AS BACTERICIDES FOR GRAMPOSITIVE BACTERIA RESISTANT TO METHICILLIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
| US-5620969-A | BACTERICIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0680468-A1 | SUBSTITUTED AMINO COMPOUNDS, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THROMBOCYTE AGGREGATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075734-A1 | PEPTOID AFFINITY LIGANDS | SLC7A1, CD74, CD2BP2 | MAOA 4736/4885MAOB 4742/4885MEN1 2646/4885 |
| US-10065988-B2 | Peptoid affinity ligands | SLC7A1, CD74, CD2BP2 | MAOA 4736/4885MAOB 4742/4885MEN1 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.